1. Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome.
- Author
-
Baumelou, Marion, Payssot, Alexandre, Row, Celine, Racine, Jessica, Lafon, Ingrid, Bastie, Jean‐Noél, Chevreux, Steeve, Chrétien, Marie‐Lorraine, Maynadié, Marc, Caillot, Denis, and Guy, Julien
- Subjects
MULTIPLE myeloma ,THERAPEUTICS - Abstract
Keywords: early assessment; flow cytometry; measurable residual disease; multiple myeloma; outcome EN early assessment flow cytometry measurable residual disease multiple myeloma outcome e82 e85 4 06/14/22 20220615 NES 220615 Multiple myeloma (MM) treatment has evolved remarkably with the introduction of new agents such as proteasome inhibitors, immunomodulatory drugs (IMIDS) and therapeutic antibodies. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. The 26 patients with persistent positive MRD had worse PFS compared to the negative MRD post- and pre-ASCT cases (24 months vs 45 months vs 68 months, I p i < 0.0001). [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF